Inclusion Criteria:

          -  PHASE I: Patients must have histologically confirmed, unresectable locally
             advanced/metastatic solid tumour with positive expression of MAGE-A3 (primary or
             metastatic lesion) and for which there is no known life prolonging standard therapy.

          -  PHASE II: Patients must have histologically confirmed, unresectable locally
             advanced/metastatic solid tumour with positive expression of MAGE-A3 (primary or
             metastatic lesion) as follows:

               1. Non-small cell lung cancer (NSCLC) specifically adenocarcinoma and squamous cell
                  carcinoma.

               2. Breast cancer

               3. Esophageal/GEJ cancer/gastric

          -  In phase II patients may be treated before refractory, such as while stable post
             treatment response to first line therapy.

          -  Presence of clinically and/or radiologically documented disease. At least one site of
             disease must be unidimensionally measurable by CT with IV contrast as follows:

               -  Chest x-ray ≥ 20 mm

               -  CT scan (with slice thickness of ≤ 5 mm) ≥ 10 mm-->Longest diameter

               -  Physical exam (using calipers) ≥ 10 mm

               -  Lymph nodes by CT scan ≥ 15 mm -->Measured in short axis

          -  All radiology studies must be performed within 14 days prior to registration (within
             21 days if negative).

          -  Patients must have at least one additional tumour mass amenable to core needle or
             excisional biopsy (Note FNA is not acceptable) that is not a measurable lesion that
             will be used as a target lesion. Patients must consent to and be willing and able to
             undergo at least two core needle biopsies of that lesion.

          -  Age ≥ 18 years

          -  ECOG performance status of 0 or 1

          -  Patients must have received at least one prior standard first line regimen for
             advanced or metastatic disease. The regimen may have been cytotoxic chemotherapy,
             targeted therapy, hormonal therapy (for e.g. anastrozole) or immunotherapy providing
             considered a standard first line therapy. There is no limit to the number of prior
             regimens but investigators and their patients should carefully consider the likelihood
             of benefit of an immunologic therapy in heavily pretreated patients.

          -  For phase II, patients may be enrolled prior to disease progression, provided they
             have completed their first line therapy as below and they have documented stable
             disease on two consecutive tumour assessments (i.e. do not have evidence of tumour
             regression from therapy):

               -  NSCLC patients may be entered after a minimum of 4-6 cycles of first line
                  combination chemotherapy; if the patient is >70 years a single agent regimen is
                  acceptable. If the patient has documented EGFR or ALK mutations, treatment they
                  may have received may include an EGFR inhibitor or ALK inhibitor as first line
                  therapy.

               -  Breast cancer patients may be entered after a minimum of 6 cycles of first line
                  therapy.

               -  Patients with metastatic/recurrent esophageal carcinoma may be entered after
                  first line chemotherapy for metastatic disease.

          -  Washout period between last day of prior treatment and planned start of treatment is
             the longest of one of the following:

               -  two weeks

               -  standard cycle length of prior regimen

               -  10 half-lives for investigational drugs.

               -  30 days since last dose of ipilumumab or PR1/PDL1 therapy.

          -  Patients must have recovered from any treatment related toxicities prior to
             registration (unless grade 1, irreversible and considered not clinically significant).
             Progression must be documented post radiotherapy if was given to the only site of
             measurable disease.

          -  Patients may have had prior radiation therapy. A minimum of 28 days (4 weeks) must
             have elapsed between the last dose of radiation and date of registration (14 days for
             a single palliative fraction of radiation to a non-target lesion). Patients must have
             recovered from any acute toxic effects from radiation prior to registration (unless
             grade 1, irreversible and considered not clinically significant).

          -  Previous surgery is permitted. A minimum of 28 days (4 weeks) must have elapsed
             between any major surgery and date of registration (7 days for minor surgery),
             provided that wound healing has occurred.

          -  Laboratory requirements done within 7 days prior to registration:

               -  WBC ≥ 3.0 x 10^9/L

               -  absolute neutrophils ≥ 1.5 x 10^9/L

               -  platelets ≥ 75 x 10^9/L

               -  INR ≤ 1.2

               -  bilirubin ≤ 1.5 x UNL (upper normal limit)

               -  AST and ALT ≤ 3.0 x UNL or ≤ 5.0 x UNL if patient has liver metastases

               -  serum creatinine ≤ 1.5 x UNL or creatinine clearance ≥ 60ml/min

               -  serum phosphate > 0.8mMol/L (grade 0-1)

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to registration
             and prior to tests which are considered to be study specific

          -  Patients who cannot give informed consent (i.e. mentally incompetent patients, or
             those physically incapacitated such as comatose patients) are not to be recruited into
             the study. Patients competent but physically unable to sign the consent form may have
             the document signed by their nearest relative or legal guardian. Each patient will be
             provided with a full explanation of the study before consent is requested.

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre.

          -  Pre-treatment biopsy must be done within 5 working days after registration and
             treatment is to begin within 5 working days of the pre-treatment biopsy (max. 10
             working days from registration).

        Exclusion Criteria:

          -  Patients with a history of other active or current malignancies that require active
             treatment

          -  Patients with known symptomatic brain metastases. Patients with treated and radiologic
             or clinical evidence of stable brain metastases, are eligible providing that they have
             been stable for at least 3 months, are asymptomatic and do not require corticosteroids
             (must have discontinued steroids at least 1 month prior to entry).

          -  Patients receiving concurrent treatment with other anti-cancer therapy or other
             investigational agents.

          -  Patients who have had prior treatment with AdVAC, MG1MA3 or any MAGE-A3 targeted
             therapy.

          -  Pregnant or lactating women. Men and women of childbearing potential who do not agree
             to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry and for the duration of the study participation.

          -  Serious illness or medical condition which would not permit the patient to be managed
             according to the protocol, including, but not limited to:

               1. History of significant neurologic or psychiatric disorder (e.g. uncontrolled
                  psychotic disorders) which would impair the ability to obtain consent or limit
                  compliance with study requirements.

               2. Active uncontrolled or serious infection (viral, bacterial or fungal) or a
                  history of opportunistic infection associated with an immunodeficient state.

               3. Significant immunodeficiency due to underlying illness (e.g. known HIV/AIDS)
                  and/or medication (e.g. systemic corticosteroids).

               4. Known myeloproliferative disorders requiring systemic therapy.

               5. Other medical conditions that might be aggravated by study treatment.

          -  Patients with uncontrolled pre-existing cardiovascular conditions and/or symptomatic
             cardiac dysfunction.

          -  Patients with household contacts meeting any of the following criteria are ineligible
             for study entry unless alternate living arrangements can be made:

               1. Women who are pregnant or nursing an infant

               2. Children < 12 months old

               3. Anyone with significant immunodeficiency due to underlying illness (e.g.
                  HIV/AIDS) and/or medication (e.g. systemic corticosteroids)

          -  Use of anti-viral medication, steroids, immunosuppressive agents (cyclosporine,
             interferon) or immunization (including the flu shot) within 14 days prior to
             registration. Use of anti-viral, anti-platelet, or anti-coagulation medication that
             cannot be discontinued within 14 days of enrollment.

          -  Patients with disease/tumour invading a major vascular structure (e.g. carotid
             artery), tumour related impending bowel obstruction or clinically significant and/or
             rapidly accumulating ascites, pericardial or pleural effusions.

          -  Patients with conditions likely to have resulted in splenic dysfunction (e.g.
             splenectomy, sickle cell anemia, radiation to the spleen ≥ 20Gy, congenital
             asplenism).

          -  Patients with ≥ grade 2 dyspnea and/or requirement for supplemental oxygen. Patients
             with important pulmonary disease must complete a 6 minute ambulation test with O2
             states ≥ 90% to be eligible